B. Gerber, M. Freund, and T. Reimer, Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, Breast Cancer, vol.107, pp.85-91, 2016.

P. Y. Salaün, R. Abgral, and O. Malard, Good clinical practice recommendations for the use of PET/CT in oncology, Eur J Nucl Med Mol Imaging, 2019.

L. M. Peterson, B. F. Kurland, and E. K. Schubert, A phase 2 study of 16?-[ 18 F]-fluoro-17?-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC), Mol Imaging Biol, vol.16, pp.431-440, 2014.

A. G. De-lucas, A. J. Schuhmacher, and M. Oteo, Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas, PLoS One, vol.11, p.158634, 201627.

Y. W. Jauw, C. W. Menke-van-der-houven-van-oordt, and O. S. Hoekstra, Immunopositron emission tomography with Zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials?, Front Pharmacol, vol.7, p.131, 2016.

G. A. Ulaner, S. K. Lyashchenko, and C. Riedl, First-in-human human epidermal growth factor receptor 2-targeted imaging using 89 Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast cancer, J Nucl Med, vol.59, pp.900-906, 2018.

D. M. Goldenberg, F. Deland, and E. Kim, Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning, N Engl J Med, vol.22, pp.1384-1386, 1978.

D. M. Goldenberg, E. E. Kim, D. Land, and F. H. , Radioimmunodetection of cancer with radioactive antibodies to carcinoembryonic antigen, Cancer Res, vol.40, pp.2984-2992, 1980.

P. Lind, M. G. Smola, and P. Lechner, The immunoscintigraphic use of Tc-99m-labelled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer, Int J Cancer, vol.47, pp.865-874, 1991.

D. M. Goldenberg, H. Abdel-nabi, and C. L. Sullivan, Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma, Cancer, vol.89, pp.104-115, 2000.

E. Dotan, S. J. Cohen, and A. N. Starodub, Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer, J Clin Oncol, vol.35, pp.3338-3346, 2017.

K. Kalinsky, S. J. Isakoff, and S. M. Tolaney, Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ?3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC), San Antonio Breast Cancer Symposium, pp.4-8, 2018.

U. San-antonio, , pp.2-11

A. Bardia, I. A. Mayer, and L. T. Vahdat, Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer, N Engl J Med, vol.380, pp.741-751, 2019.

P. Peltier, C. Curtet, and J. F. Chatal, Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer, J Nucl Med, vol.34, pp.1267-1273, 1993.

J. Barbet, P. Peltier, and S. Bardet, Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA/anti-DTPA-indium bispecific antibody, J Nucl Med, vol.39, pp.1172-1178, 1998.

A. Oudoux, P. Salaun, and C. Bournaud, Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy, J Clin Endocrinol Metab, vol.92, pp.4590-4597, 2007.

E. A. Rossi, D. M. Goldenberg, and T. M. Cardillo, Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci USA, vol.103, pp.6841-6846, 2006.

C. Bodet-milin, A. Faivre-chauvet, and T. Carlier, Immuno-PET using anticarcinoembryonic antigen bispecific antibody and 68Ga-labeled peptide in metastatic medullary thyroid carcinoma: clinical optimization of the pretargeting parameters in a first-in-human trial, J Nucl Med, vol.57, pp.1505-1511, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01415668

S. Waaijer, F. J. Warnders, and S. Stienen, Molecular imaging of radiolabeled bispecific T-cell engager 89Zr-Amg211 targeting cea-positive tumors, Clin Cancer Res, vol.24, pp.4988-4996, 2018.

H. L. Yang, T. Liu, and X. M. Wang, Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy, Eur Radiol, vol.21, pp.2604-2617, 2011.

R. Piva, F. Ticconi, and V. Ceriani, Comparative diagnostic accuracy of 18 F-FDG PET/CT for breast cancer recurrence, Breast Cancer, vol.9, pp.461-471, 2017.

A. Sanchez-crespo, Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography, Appl Radiat Isot, vol.76, pp.55-62, 2013.

D. Laessig, D. Nagel, and V. Heinemann, Importance of CEA and CA15-3 during disease progression in metastatic breast cancer patients, Anticancer Res, vol.27, pp.1963-1968, 2007.

R. Schoffelen, W. T. Van-der-graaf, and R. M. Sharkey, Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method, EJNMMI Res, vol.2, p.5, 2012.

S. Benchimol, A. Fuks, and S. Jothy, Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule, Cell, vol.57, pp.327-334, 1989.

R. Schoffelen, O. C. Boerman, and D. M. Goldenberg, Development of an imagingguided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results, Br J Cancer, vol.109, pp.934-942, 2013.